<DOC>
	<DOCNO>NCT01138579</DOCNO>
	<brief_summary>This study investigator drive , open-label , non-randomized , uncontrolled , dose escalate Phase I/II study evaluate safety preliminary efficacy trifunctional bispecific antibody FBTA05 combination donor lymphocyte infusion ( DLI ) treatment relapse refractory disease CD20 positive either low- high-grade non-Hodgkin´s lymphoma allogeneic transplantation</brief_summary>
	<brief_title>Study Trifunctional Antibody FBTA05 Donor Lymphocyte Infusion B-cell Lymphoma After Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Patient´s write informed consent ≥ 18 year age ; male female Confirmed CLL , low grade NHL high grade NHL standard histological immunophenotypical criterion describe WHO classification lymphoid malignancy CD20 positivity ( already confirm ) Adequate haematological , liver kidney function Platelet count ≥25,000mm³ ( =25 x 10^9/l ) Patients active disease ( relapsed/refractory ) survive least 60 day allogeneic transplantation Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; =2 ( Appendix IV ) Negative pregnancy test ( 2 day enrolment ) adequate contraception study woman child bear potential ( pre menopausal , &lt; 2 year postmenopausal surgically sterile ) Any antiCD20 / antiT cell direct antibody treatment &lt; 3 month application FBTA05 Positivity human antimouse antibody ( HAMAs ) History GvHD ° III IV , GvHD require steroid therapy 10 mg/day Known suspect hypersensitivity recombinant , murine rat protein AST/SGOT great 10 x ULN ( grade 3 , CTCAE ) Bilirubin great 5 x ULN ( grade 3 , CTCAE ) Creatinine great 3.5 mg/dl ( grade 3 , CTCAE ) Acute uncontrolled chronic infection , viral infection risk reactivation ( e.g.HCV , HBV , HIV ) Unable unwilling comply fully protocol Any condition judgement Investigator would place subject undue risk interfere result study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>FBTA05</keyword>
	<keyword>CD20</keyword>
	<keyword>CLL</keyword>
	<keyword>NHL</keyword>
	<keyword>DLI</keyword>
	<keyword>allogeneic transplantation</keyword>
	<keyword>CD20 positive chronic lymphocytic leukemia ( CLL )</keyword>
	<keyword>low high grade non-Hodgkin´s lymphoma ( NHL ) allogeneic stem cell transplantation active disease</keyword>
</DOC>